Literature DB >> 18593873

DLC1: a significant GAP in the cancer genome.

Aurelia Lahoz1, Alan Hall.   

Abstract

Rho GTPases are believed to make important contributions to the development and progression of human cancer, but direct evidence in the form of somatic mutations analogous to those affecting Ras has been lacking. A recent study in Genes & Development by Xue and colleagues (1439-1444) now provides in vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593873      PMCID: PMC2732422          DOI: 10.1101/gad.1691408

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  62 in total

1.  Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis.

Authors:  Raffaella Sordella; Wei Jiang; Guang-Chao Chen; Marcello Curto; Jeffrey Settleman
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

Review 2.  Tensin.

Authors:  Su Hao Lo
Journal:  Int J Biochem Cell Biol       Date:  2004-01       Impact factor: 5.085

3.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.

Authors:  M Trahey; F McCormick
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

4.  DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.

Authors:  Bao-Zhu Yuan; Amy M Jefferson; Kimberly T Baldwin; Snorri S Thorgeirsson; Nicholas C Popescu; Steven H Reynolds
Journal:  Oncogene       Date:  2004-02-19       Impact factor: 9.867

5.  V599EB-RAF is an oncogene in melanocytes.

Authors:  Claudia Wellbrock; Lesley Ogilvie; Douglas Hedley; Maria Karasarides; Jan Martin; Dan Niculescu-Duvaz; Caroline J Springer; Richard Marais
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

6.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Authors:  Wen Xue; Alexander Krasnitz; Robert Lucito; Raffaella Sordella; Linda Vanaelst; Carlos Cordon-Cardo; Stephan Singer; Florian Kuehnel; Michael Wigler; Scott Powers; Lars Zender; Scott W Lowe
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

Review 7.  Human RAS superfamily proteins and related GTPases.

Authors:  John Colicelli
Journal:  Sci STKE       Date:  2004-09-07

8.  Transforming activity of human tumor DNAs.

Authors:  T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

9.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

10.  Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells.

Authors:  Xiaoling Zhou; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Oncogene       Date:  2004-02-12       Impact factor: 9.867

View more
  46 in total

1.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

3.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Authors:  Xuyu Yang; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Cancer Res       Date:  2011-03-03       Impact factor: 12.701

4.  mDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasion.

Authors:  Masahiro Tanji; Toshimasa Ishizaki; Saman Ebrahimi; Yuko Tsuboguchi; Taiko Sukezane; Tsuyoshi Akagi; Margaret C Frame; Nobuo Hashimoto; Susumu Miyamoto; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

5.  Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.

Authors:  Xiaoling Zhou; Xu-Yu Yang; Nicholas C Popescu
Journal:  Biochem Biophys Res Commun       Date:  2012-03-07       Impact factor: 3.575

6.  DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.

Authors:  Veenu Tripathi; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

7.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis.

Authors:  Szu-Wei Lee; Chien-Feng Li; Chia-Hsin Chan; Jing Wang; Wei-Lei Yang; Ching-Yuan Wu; Juan Wu; Keiichi I Nakayama; Hong-Yo Kang; Hsuan-Ying Huang; Mien-Chie Hung; Pier Paolo Pandolfi; Hui-Kuan Lin
Journal:  Nat Cell Biol       Date:  2010-04-11       Impact factor: 28.824

8.  RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Authors:  Emilie Malissein; Elise Meunier; Isabelle Lajoie-Mazenc; Claire Médale-Giamarchi; Florence Dalenc; Sophie F Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-06       Impact factor: 4.553

9.  A novel approach to tag and identify geranylgeranylated proteins.

Authors:  Lai N Chan; Courtenay Hart; Lea Guo; Tamara Nyberg; Brandon S J Davies; Loren G Fong; Stephen G Young; Brian J Agnew; Fuyuhiko Tamanoi
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

10.  DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.

Authors:  Patrik Erlmann; Simone Schmid; Florian A Horenkamp; Matthias Geyer; Thomas G Pomorski; Monilola A Olayioye
Journal:  Mol Biol Cell       Date:  2009-08-26       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.